Jessica Wiley, Author at ELIAS Animal Health

National Veterinary Technician Week: Celebrating The Resilience of Those In This Vital Role

National Veterinary Technician Week is celebrated October 16-22, and this year the theme is: “Veterinary Technicians’ Resilience is the Heart of Veterinary Medicine.” Veterinary technicians are the men and women who seamlessly execute veterinary patient care. Serving on the frontlines of animal care, their resiliency and passion to provide the best care for their patients is what makes the veterinary technician role so vital. In human medicine, several people would fill the role of one veterinary technician: nurse, x-ray technician, phlebotomist, EMT, surgical technician…the list goes on. What is a Veterinary Technician? Veterinary technicians are credentialed professionals whose medical knowledge and clinical skills provide routine and emergency care. They work alongside veterinarians to provide the medical care that helps animals live healthy, happy lives. Vet techs play an important role in veterinary patient care. Their attention to detail ensures that each patient receives proper care, no matter what ails them. [...]

By Jessica Wiley|2022-10-10T10:26:07-06:00October 10th, 2022|Categories: Blog|Tags: veterinary technician|0 Comments

Three Ways Apheresis Is Used in Veterinary Medicine

What is Apheresis? Apheresis is a nonsurgical treatment where a patient’s blood is withdrawn from the body to separate plasma and cells and is often used to treat patients with autoimmune diseases, those suffering from blood intoxications—such as overdoses and poisonings—as well as cancer. In humans, apheresis is also the process by which donations of plasma, platelets and red blood cells are donated. These types of donations are different than a whole blood donation; apheresis is required to extract specific components of the blood and then return the remaining components to the donor. On Apheresis Awareness Day, ELIAS Animal Health recognizes and applauds apheresis practitioners around the world who are advancing this important therapy in both human and animal medicine. We also honor the many generous donors who help to save countless lives. Access to apheresis in veterinary medicine has more than doubled in the past 3 years, and [...]

By Jessica Wiley|2022-09-21T11:29:32-06:00September 19th, 2022|Categories: Blog|Tags: adoptive cell therapy, apheresis, ECI, immunotherapy|0 Comments

ELIAS Animal Health Research Demonstrates Cancer-Killing Capabilities of Its Activated T Cell Immunotherapy

In vitro study of the ELIAS Cancer Immunotherapy (ECI®) showed personalized T cell immunotherapy initiated a significant immune response against target cancer cells. OLATHE, Kan., August 10, 2022 -- ELIAS Animal Health recently presented new mechanism of action data for the ELIAS Cancer Immunotherapy (ECI®) at the 2022 American College of Veterinary Internal Medicine Forum. ECI is an adoptive cell therapy that stimulates a patient’s immune system to recognize and attack cancers. ECI uses a personalized vaccine made from a patient’s own cancer cells to “prime” the immune cells to recognize the cancer. These primed immune cells—which are collected from the patient through a procedure called apheresis—are activated and expanded ex vivo for reinfusion into the patient, where they travel to the cancer cells and attack them. In vitro study demonstrates how vaccine-primed T cells mount an immune response against cancer cells [...]

By Jessica Wiley|2022-12-12T13:42:11-06:00August 10th, 2022|Categories: News, Press Releases|Tags: adoptive cell therapy, cancer immunotherapy, canine cancer, canine osteosarcoma, ECI|0 Comments

PODCAST: ELIAS CEO talks immunotherapy and canine osteosarcoma on Dog Cancer Answers

ELIAS Animal Health CEO, Tammie Wahaus, was a recent guest on the Dog Cancer Answers podcast to discuss how the ELIAS Cancer Immunotherapy (ECI) works, the role of a healthy immune system in successful immunotherapy, and why we chose to focus on canine osteosarcoma first. Listen to the episode below, or read the full transcript at Dog Cancer Answers online. Listen to more episodes of the Dog Cancer Answers podcast here.

By Jessica Wiley|2022-10-20T13:12:00-06:00June 1st, 2022|Categories: Blog|Tags: cancer immunotherapy, canine cancer, canine osteosarcoma, ECI, podcast|0 Comments

PODCAST: ELIAS CEO Discusses Treatment Option for Bone Cancer in Dogs on Fuzzybutts & Friends

ELIAS Animal Health CEO, Tammie Wahaus, was the featured guest on the Fuzzybutts & Friends podcast. Hosted by Luke Robinson, founder of the PuppyUp Foundation, the podcast explores how the ELIAS Cancer Immunotherapy (ECI®) works against bone cancer in dogs, as well as how ELIAS is committed to developing more immunotherapies for pets with cancer. Check out the episode below! Learn more about the PuppyUp Foundation here. Watch more episodes of the Fuzzybutts & Friends podcast here.

By Jessica Wiley|2022-07-17T12:48:00-06:00April 29th, 2022|Categories: Blog|Tags: canine cancer, canine osteosarcoma, ECI|0 Comments

What Does the Future of Canine Cancer Treatment Look Like?

Immunotherapy is increasingly becoming an important tool in the oncologist’s arsenal to improve clinical outcomes for both human and veterinary patients alike. Studies have shown that immunotherapies can produce durable responses in some patients, both human and companion animals. The power of combining immuno-oncology approaches such as adoptive cell therapies, oncolytic viruses, and checkpoint inhibitors, among others, has the potential to significantly increase the number of patients that become long term survivors. The article, "The future of canine cancer treatment" discusses the research ELIAS Animal Health is doing to evaluate how to improve patient response rates with these combination approaches. Read the full article at Veterinary Practice News online.

By Jessica Wiley|2022-03-24T19:48:24-06:00March 16th, 2022|Categories: Blog|Tags: adoptive cell therapy, canine cancer, immunotherapy|0 Comments

ELIAS Cancer Immunotherapy Gives Dogs with Osteosarcoma More Days at Home

Recent advancements in canine cancer treatment offer the potential for better outcomes, especially the advancements in immunotherapy treatments. A discussion of the ELIAS cancer immunotherapy (ECI®) for the treatment of canine osteosarcoma in Clinician's Brief pointed out that "ECI is the only 2-step immunotherapy in veterinary medicine that has the potential to match or exceed the current standard of care while reducing or eliminating the need for chemotherapy." The article, "Osteosarcoma Immunotherapy for More Days at Home," discusses the evidence-based science behind ECI, the potential benefits over chemotherapy, and how referring veterinarians play an active and vital role in the care continuum. Read the full article at Clinician's Brief online.

By Jessica Wiley|2022-03-16T17:51:21-06:00February 22nd, 2022|Categories: Blog|Tags: cancer immunotherapy, canine osteosarcoma, ECI|0 Comments

ELIAS Animal Health Expands Scientific Advisory Board

Nov. 23, 2021 — ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announces the appointment Zachary Wright, DVM, DACVIM (Oncology) and Amanda Foskett, DVM, DACVIM (Oncology) to its scientific advisory board. “I am pleased to add two veterinary oncologists to our advisory board," said Tammie Wahaus, CEO of ELIAS Animal Health. "Drs. Wright and Foskett bring an invaluable perspective on the advancement of animal cancer treatments.” Dr. Wright is the Medical Director at Animal Diagnostics Clinic at VCA Hospitals in Dallas, Texas. He received his veterinary medical degree from Texas A&M University and completed a one year rotating small animal internship in medicine and surgery at VCA West Los Angeles Animal Hospital in Los Angeles, California. Dr. Wright completed his residency in small animal oncology at Texas A&M University and became a Diplomate of the American College of Veterinary Internal Medicine-Oncology in [...]

By Jessica Wiley|2024-04-30T11:48:54-06:00November 23rd, 2021|Categories: News|Tags: elias leadership|0 Comments

ELIAS Animal Health In-Licenses Oncolytic Vaccinia Virus Treatment for Pet Animals from Genelux Corporation

Agreement grants ELIAS Animal Health the worldwide right to development and commercialization of V-VET1 for the diagnosis, prevention and treatment of cancer in veterinary medicine Nov. 18, 2021 -- Genelux Corporation, a clinical-stage immunotherapy company, recently announced a licensing agreement with ELIAS Animal Health for V-VET1, its clinical-stage animal health product candidate. V-VET1 is a vaccinia viral strain which selectively replicates in cancer cells causing cell death (apoptosis). ELIAS Animal Health is planning clinical trials to evaluate and develop V-VET1 as a potential new immunotherapy option for veterinary oncologists. “We are thrilled to announce our exclusive license for V-VET1 to help veterinarians treat the many pets who are diagnosed with cancer every year,” said Tammie Wahaus, CEO of ELIAS Animal Health. “Companion animal cancer treatments have made little progress in the past few decades, and this partnership is an exciting step in broadening the cancer treatment options available in veterinary medicine.” [...]

By Jessica Wiley|2024-04-30T11:41:10-06:00November 18th, 2021|Categories: News|Tags: cancer immunotherapy, genelux corporation, oncolytic virus|0 Comments

ELIAS Animal Health Launches Clinical Trial Of Cancer Immunotherapy Treatment For Canine Oral Melanoma

Olathe, Kan., August 31, 2021 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, today announced the initiation of a pilot study of its adoptive T cell therapy combined with surgery and radiotherapy, if indicated, for dogs diagnosed with oral malignant melanoma, a highly metastatic disease and the most common form of oral cancer seen in dogs. Melanoma is widely believed to be chemo-resistant and in this study the adoptive T cell therapy will be administered instead of chemotherapy. This clinical trial will enroll dogs that have been newly diagnosed with oral melanoma but have not yet been treated for their cancer. It is a multi-center, single-arm study with no randomization. ELIAS is providing financial assistance that will substantially cover costs of participation and treatment in the trial. A list of participating sites can be found on the website. Adoptive T cell therapy is [...]

By Jessica Wiley|2022-01-08T14:27:30-06:00August 31st, 2021|Categories: News, Press Releases|Tags: clinical trial, oral melanoma|0 Comments

About Jessica Wiley